Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 19, 2008

Merck Serono to Use Biolex’ Technology for Antibody Optimization

  • Merck Serono plans to use Biolex Therapeutics’ LEX System to evaluate antibody optimization and production. Merck Serono will investigate whether this platform has the ability to improve therapeutic profiles of its antibody candidate through optimization of antibody glycosylation structures.

    Biolex engineered the LEX System to produce antibodies with a fully human glycosylation structure without fucose. The technology also has the ability to produce antibodies that have a fully G0 glycosylation structure, lacking galactose, the company adds. These two innovations reportedly produce antibodies with greater efficacy and potency, less side effects, and reduced infusion times.

  • You’re all set! Thank you for subscribing to GEN Highlights.